Zymeworks becomes the latest mesothelin dropout
The group cans ZW171 after “on-target, off-tumour toxicity”.
The group cans ZW171 after “on-target, off-tumour toxicity”.
It’s a new term for biotech and its investors.
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
Data on J&J’s Tecvayli and Pfizer’s Elrexfio in relapsed multiple myeloma are due soon.